Endobronchial coils for emphysema: Dual mechanism of action on lobar residual volume reduction.

Journal Article (Journal Article;Multicenter Study)

BACKGROUND AND OBJECTIVE: The RENEW trial demonstrated that bronchoscopic lung volume reduction using endobronchial coils improves quality of life, pulmonary function and exercise performance. In this post hoc analysis of RENEW, we examine the mechanism of action of endobronchial coils that drives improvement in clinical outcomes. METHODS: A total of 78 patients from the RENEW coil-treated group who were treated in one or both lobes that were deemed as the most destroyed were included in this retrospective analysis. Expiratory and inspiratory HRCT scans were used to assess lobar volume change from baseline to 12 months post coil treatment in treated and untreated lobes. RESULTS: Reduction in lobar RV in treated lobes was significantly associated with favourable clinical improvement. Independent predictor of the change in RV and FEV1 was the change in lobar RV reduction in the treated lobes and for change in 6MWD the absence of cardiac disease and the change in SGRQ, while the independent predictor of change in SGRQ was the change in 6MWD. CONCLUSION: Our results suggest that residual lobar volume reduction in treated lobes measured by QCT is the driving mechanism of action of endobronchial coils leading to positive clinical outcomes. However, the improvement in exercise capacity and quality of life seems to be affected by the presence of cardiac disease.

Full Text

Duke Authors

Cited Authors

  • Hartman, JE; Shah, PL; Sciurba, F; Herth, FJF; Slebos, D-J; RENEW Study Group,

Published Date

  • November 2020

Published In

Volume / Issue

  • 25 / 11

Start / End Page

  • 1160 - 1166

PubMed ID

  • 32267059

Pubmed Central ID

  • PMC7687244

Electronic International Standard Serial Number (EISSN)

  • 1440-1843

Digital Object Identifier (DOI)

  • 10.1111/resp.13816

Language

  • eng

Conference Location

  • Australia